Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era
Author:
Affiliation:
1. Analysis Group Inc., Los Angeles, CA, USA
2. ADC Therapeutics Inc., New Providence, NJ, USA
3. Department of Lymphoma–Myeloma, Division of Cancer Medicine, University of Texas, Houston, TX, USA
4. Analysis Group Inc., New York, NY, USA
Funder
ADC Therapeutics Inc
ADC Therapeutics Inc.
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1957806
Reference52 articles.
1. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
2. null
3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
5. Predictors of early vs late diffuse large B cell lymphoma (DLBCL) relapses in the Rituximab era.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events;Current Medical Research and Opinion;2024-05-24
2. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study;Haematologica;2023-08-31
3. Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia;Cancers;2023-04-22
4. Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2022-08
5. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma;Advances in Therapy;2022-04-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3